Results 171 to 180 of about 6,539 (200)

Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial

Lancet, The, 2016
Eugene R Bleecker, J Mark Fitzgerald, Pascal Chanez   +2 more
exaly  

Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studies

Lancet Respiratory Medicine,the, 2020
Dave Singh, Àlvar Agustí, Alberto A Papi   +2 more
exaly  

Benralizumab/omalizumab

Reactions Weekly, 2022
openaire   +2 more sources

Benralizumab for the Prevention of COPD Exacerbations

New England Journal of Medicine, 2019
Bartolome R Celli, Christopher E Brightling, Àlvar Agustí   +2 more
exaly  

Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma

New England Journal of Medicine, 2017
Parameswaran Nair, Sally E Wenzel, Klaus F Rabe   +2 more
exaly  

Aminophylline/benralizumab

Reactions Weekly, 2023
openaire   +1 more source

Benralizumab/vedolizumab

Reactions Weekly, 2023
openaire   +1 more source

Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study

Lancet Respiratory Medicine,the, 2014
Christopher E Brightling, Eugene R Bleecker, Reynold A Panettieri   +2 more
exaly  

Benralizumab/mepolizumab

Reactions Weekly, 2022
openaire   +1 more source

Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study

Lancet, The
Brian D Kent
exaly   +2 more sources